Friday, June 26, 2020

Chinese fibromyalgia Market: Historical, Current and Projected Market Size, Competitive landscape & Forecast 2022

Chinese Fibromyalgia Market Research Report: By Diagnosis (Laboratory Evaluation, Presence Of Central Sensitization), Treatment (Targeted (Antidepressants, Anti-Seizure Drugs), Symptomatic Treatment, End Users (Hospitals &Clinics) – Forecast Till 2022
Market Highlights:
The Chinese fibromyalgia Market is expected to grow at a CAGR of 18.7% during the forecast period 2017-2022.Fibromyalgia syndrome co-exists with other painful conditions, such as migraine and other types of headaches, temporomandibular joint disorders, irritable bowel syndrome (IBS), and interstitial cystitis. The treatment of fibromyalgia includes both targeted and symptomatic approach. Till date, there are only three FDA approved drugs for the fibromyalgia treatment, i.e., Lyrica (PFIZER), Cymbalta (Eli Lilly and Company), and Savella (Allergan plc). However, there are few other drugs prescribed by physicians to control the symptoms of fibromyalgia such as pain relievers, muscle relaxants, and traditional Chinese medicine.
Growing geriatric population, increasing cases of rheumatic diseases, growing awareness among the population, and rising incidences of traumatic stress and road accidents are the key factors driving the Chinese fibromyalgia market. According to a study published in the Arthritis Care & Research journal in 2017, fibromyalgia and related symptoms worsen the functional status of individuals with rheumatoid arthritis. Around 15%-30% of patients with rheumatic disorders have co-morbid fibromyalgia syndrome.
However, difficulty in diagnosis of the disease, and stringent FDA regulations may hinder the growth of the market to an extent. As fibromyalgia syndrome is associated with other chronic diseases so, its diagnosis takes a long time. As fibromyalgia syndrome is associated with other chronic diseases so, its diagnosis takes a long time. According to a study published in Arthritis Research & Therapy journal in 2017, in Taiwan, the risk of coronary heart disease in fibromyalgia patients was 47% higher than the general population.
Key Players
Some of key the players in the market are Pfizer, GlaxoSmithKline, AstraZeneca, Roche, Astellas Pharma, Eli Lilly and Company, Johnson & Johnson Services, Inc., SANOFI, Bayer AG, AbbVie, ALLERGAN, Boehringer Ingelheim, Cephalon, Inc., Vertical Pharmaceuticals, Sunovion Pharms Inc, Jazz Pharmaceuticals, ABBOTT, NOVARTIS, and others.
Regional Analysis
South Central China accounted for the major share of the market owing to the rising prevalence of fibromyalgia in this region. Rising cases of chronic rheumatic diseases are also capable of fuelling the fibromyalgia market in China. Prevalence of rheumatoid arthritis is around 0.35%, with the significantly higher rate in Northern China as compared to the Southern part.
The rising healthcare expenditure is also propelling the growth of the market. In China, the total expenditure on health per capita in 2014 was USD 731, as per the World Health Organization (WHO) in 2015. The health expenditure in China grew at a rate of 11.6% per year, suggested by a study published in BMC Health Services Research journal in 2017. This rate is much faster than the growth of the country’s economy, i.e., 9.9% per year.
Segmentation
The Chinese fibromyalgia market is segmented on the basis of diagnosis, treatment, and end-user.
On the basis of the diagnosis, the market is classified into laboratory evaluation and presence of central sensitization.
On the basis of the treatment, the market is segmented into targeted treatment and symptomatic treatment.
On the basis of the end-users, the market is segmented into hospitals, clinics, diagnostic centers, and others.
NOTE: Our Team of Researchers are Studying Covid19 and its Impact on Various Industry Verticals and Wherever Required We Will be Considering Covid19 Footprints for a Better Analysis of Markets and Industries. Cordially Get in Touch for More Details.
Posted by at No comments:

Wound Debridement Products Market Growth Size Overview, Opportunities, In-Depth Analysis and Forecasts 2023

Overview:

The global Wound Debridement Products Market Growth is on a path of scaling a substantial valuation by the end of 2023 with an impressive CAGR to cover the forecast period of 2018 to 2023. Market Research Future (MRFR) announces several possibilities that can provide the market with thrust in the coming years and ensure its growth.

Factors like cost-effective measures, development of better products, inclusion of latest technologies, increased participation from manufacturers, rising expenditure for research and development, and increased awareness regarding the procedure would help the global wound debridement products market growth.

On the other hand, the slump in financial condition in some countries may restrain the wound debridement products market growth.

Segmentation:

The global wound debridement products market, as discussed by the MRFR experts, includes end-users to assist in the detailed study of the market proceedings. This segment holds various factors and data and ensures a proper study of the growth that could help in developing strategies later.

By end-users, the study on the global wound debridement products market includes nursing units, ambulatory centers, multi- specialty clinics, specialty care, and hospitals. The hospitals segment has the largest market share and it would continue to maintain its market domination during the forecast period as it helps investors to engage themselves in building a better prospect. These hospitals have infrastructures that also help skilled hands to take care of their patients. This is a major influencer for the market. The specialty care and ambulatory centers may experience substantial growth rate in the coming years.
Regional Analysis:

The global wound debridement products market is expected to get strong support from the infrastructure of the Americas. North America would play a crucial role as their investment in the healthcare sector is substantial. Europe would also get proper support from various governments as their initiatives would inspire various research works.

Competitive Analysis:

The rising demand for proper wound care treatment, the global market for wound debridement products is expected to witness a thrust from the strategic moves maintained by companies like Smith & Nephew Plc, Advanced Medical Solutions Group, ArthoCare Corporation, and MediWound Ltd. A closer study of the recent proceedings of these companies is expected to reveal growth with strategies like mergers, acquisitions, and joint ventures that would help in various expansion plans. In addition, tactics like brand promotional activities, launching of new products, spurring of the investment in the research and development sector to boost the innovation process, and others would ensure the market gets a decent chance to move ahead smoothly. MRFR has attempted to record all these moves to gauge how the market flow will impact the future outcomes.

Industry News:

In May 2020, BTIG announced that the Buy rating on Misonix (MSON) would be around a price target of $18.00. The first week of May witnessed the share price of Misonix reach a $12.08. Misonix, Inc. is a reputed medical device company with substantial focus on the development, design, manufacture, and marketing of myriad types of therapeutic ultrasonic medical devices. Its impact on the wound debridement product manufacturing is immense.

In May 2020, Sanara MedTech Inc., based out of Texas, is a provider of diverse surgical and chronic wound care products and has its focus on improving patient outcomes. The company announced today a proper execution of new license agreement with Rochal Industries, LLC. The agreement is for an autolytic debrider wound dressing that is currently under development.
NOTE: Our Team of Researchers are Studying COVID-19 and its Impact on Various Industry Verticals and Wherever Required We Will be Considering COVID-19 Footprints for a Better Analysis of Markets and Industries. Cordially Get in Touch for More Details.
Posted by at No comments:

Barlow’s Syndrome Market size by Industry Insight Analysis, Segments, Top Key Players, Drivers and Trends to 2023

Barlow’s Syndrome market research report: by type (mitral valve stenosis), treatment (medication and surgical treatment), diagnosis (X-Ray, and Echocardiogram), end-users (hospitals & surgical centers, and specialty clinics) – Global forecast till 2023

Market Highlights:
Barlow’s Syndrome is a condition in which there is an abnormality of the mitral valve of the heart. It is a condition in which the leaflets of the mitral valve swell into the left atrium of the heart as the valve closes during ventricular contraction. This abnormality prevents the valve from closing correctly, which causes it to leak.

Regional Analysis
The Americas dominate the global Barlow’s Syndrome Market owing to the rising geriatric population, increasing genetic disorders, and increasing number of injuries leading to infections. The Americas are further segmented into North America and South America. North America holds the largest market is owing to increasing number of geriatric population, rising number of cardiovascular disorders, and growing population. Additionally, a rising number of market players launching newer products, technological advancements, and market players wanting to expand their foothold is likely to drive the growth of the Barlow’s Syndrome market in the North American region. For instance, according to the National Centre for Chronic Disease Prevention (CDC), in 2015 around 630,000 Americans died of cardiovascular disorders.

Europe accounts for the second largest market due to rising cardiovascular diseases, increasing funds and increasing healthcare expenditure. For instance, according to the Eurostat, Germany incurred healthcare expenditure over EUR 321 billion in 2014.  According to European Society of Cardiology (ESC), around Euro 196 billion was spend for CVD. Germany, France, and the U.K hold a significant share of the market due to increasing demand for technologically advanced devices and increasing awareness in terms of rare diseases, and rising overall growth of the medical device industry.

The Asia Pacific is the fastest growing Barlow’s Syndrome market across the globe, whose growth is attributed to the rising geriatric population, increasing prevalence cardiovascular diseases, and rapidly developing economies. For instance, according to ESCAPE (Economic and Social Commission for Asia and the Pacific), in the year 2016, approximately 12.4% of the population was 60 years and older, and is projected to increase to 1.3 billion people by 2050. Additionally, increasing healthcare expenditure and demand for new treatment options for rare diseases fuel the market growth. India and China are the major contributors to the market growth due to the rapid development of healthcare sector and increasing healthcare expenditure in these regions and increasing demand for diagnostic services.

On the other hand, the Middle East & Africa is expected to witness limited growth due to limited access to the healthcare resources and lack of awareness about rare diseases. In the Middle East, the growth of the market is driven by increasing availability of new diagnostic and treatment methods for various chronic diseases.


Segmentation
The global Barlow’s Syndrome market is segmented on the basis of type, treatment, diagnosis, and end-users.
On the basis of the type, the market is segmented as mitral valve stenosis, mitral valve prolapse, and mitral valve regurgitation.

On the basis of the treatment, the market is segmented into medications and surgery. Medications are further sub-segmented to beta-blockers and calcium blockers. The beta blockers further sub-segmented to atenolol and metoprolol. The calcium blockers are further sub-segmented into Verapamil and Diltiazem.
On the basis of the diagnosis, the market is segmented into X-ray, electrocardiogram, and echocardiogram.
On the basis of the end user, the market is segmented into hospitals & surgical centers, research institutes, and specialty clinics.

Key Players
Some of the key players in the barlows syndrome market are Abbott, Medtronic, Edward Lifesciences Corporation, CryoLife, Inc., Boston Scientific Corporation, Micro Interventional Devices, Inc., Lepu Medical Technology Co., Ltd Neovasc, Inc., Sorin Group, TTK HealthCare, JenaValve Technology, Inc. among others

NOTE: Our Team of Researchers are Studying Covid19 and its Impact on Various Industry Verticals and Wherever Required We Will be Considering Covid19 Footprints for a Better Analysis of Markets and Industries. Cordially Get in Touch for More Details.
Posted by at No comments:

Dravet syndrome Market Analysis, Growth Factors, Development Trends and Forecast to 2023

Dravet syndrome market research information: by type of seizures (myoclonic, partial, absence seizures), diagnosis (MRI, EEG, SCN1A testing), treatment (seizure medications, ketogenic diet, vagus nerve stimulation), end-user – Global forecast till 2023

Dravet syndrome is a rare epileptic disorder affecting infants. The patient has seizures which are triggered by hot temperatures or fevers. It is also known as severe myoclonic epilepsy of infancy (SMEI). According to the National Center for Advancing Sciences, nearly 15-25% of the cases of the disorder have a family history of febrile seizures or epilepsy. The global Dravet syndrome market report by Market Research Future (MRFR) has been compiled by a blend of primary and secondary research.

Market Overview
The global Dravet syndrome Market is expected to magnify its valuation at 8.5% CAGR from 2017 to 2023 (forecast period). The increase noticed in the health expenditure for research and development (R&D) and development of new therapies are primary factors expected to drive the market growth. Other major drivers include reimbursement policies offering coverage of rare diseases, improvement in regulatory framework, and unmet medical needs of patients.
Adverse effects of the drugs, low awareness of the disease, and low planning of healthcare in low and mid income countries are some of the restraints which can impede market growth.

Segmentation
The global Dravet syndrome market is segmented on the basis of the type of seizures, diagnosis, treatment & management, and end-user.
On the basis of the type of seizures, it is classified as myoclonic seizures, atonic seizures, partial seizures, absence seizures, tonic clonic seizures, photosensitive seizures, and others.
On the basis of the diagnosis, it is segmented as magnetic resonance imaging (MRI), electroencephalography (EEG), SCN1A testing, and others.
On the basis of the treatment & management, the market is segmented into seizure medications, ketogenic diet, vagus nerve stimulation (VNS), and others. The seizure medications segment is further classified into clobazam, stiripentol, sodium valproate, and others.
On the basis of the end-user, the global Dravet syndrome market is segmented into pharmaceutical companies, hospitals, diagnostic laboratories, academic and research institutes, and others.

Request For Free Sample Copy :
https://www.marketresearchfuture.com/sample_request/5509 

 Regional Analysis

 The Americas, Europe, the Middle East & Africa (MEA), and Asia Pacific (APAC) are the major segments according to region.
The Americas are presumed to dominate the global market till 2023 due to the increased healthcare budget by governments in the region for the welfare of their patients. Presence of large number of players and continuous development of drugs due to ongoing clinical trials are other drivers of the region.
Europe, on the other hand, can enjoy massive demand due to support by government for research and development and initiatives taken by them to improve existing reimbursement insurance policies.
The APAC region is likely to witness the fastest growth due to developments in healthcare technology, drug developments undertaken by contract research organizations, and a large patient pool. The large health expenditure is an indicator of the growth of the global Dravet syndrome market in the region. According to the Australian Institute of Health and Welfare, the health expenditure in Australia was 170.4 billion in 2015-2016.
The MEA region can showcase dull growth due to poor medical infrastructure and low awareness among patients.

Competition Outlook

 Ovid Therapeutics, OPKO Health Inc., Zogenix, Inc, Biocodex, Biscayne Neurotherapeutics, Takeda Pharmaceutical Company Limited, Sage Therapeutics, Xenon Pharmaceuticals, INSYS THERAPEUTICS, INC., Epygenix Therapeutics, Inc., Thermo Fisher Life Technologies, PTC Therapeutics, GW Pharmaceuticals, plc, and Cyberonics, Inc. are the biggest players in the global Dravet syndrome market.

Industry News
Fintepla, a drug developed by Zogenix for the treatment of Dravet’s, has been approved by the U.S. FDA due to new clinical data supporting its efficacy. The results produced by the Childhood Neurology Society have produced new evidence which have been the culmination of an ongoing clinical trial with patients under the age of six

NOTE: Our Team of Researchers are Studying Covid19 and its Impact on Various Industry Verticals and Wherever Required We Will be Considering Covid19 Footprints for a Better Analysis of Markets and Industries. Cordially Get in Touch for More Details.

Posted by at No comments:

Diabetic Lancing Device Market Profile Overview, Dynamics, Supply & Demand, Analysis & Forecast by 2023

Diabetic lancing device market research report By type (push button safety lancets, pressure activated safety lancets, side button safety lancets), by gauge (17/18g, 21g, 23g, 25g, 28g,  30g), by penetration depth, by end-user – Global forecast till 2023
Diabetes is a globally recognized disease prevalent in mid-income and high income countries. According to the World Health Organization (WHO), diabetes will be one of the major causes of blindness, stroke, heart attacks, and kidney failure. Diabetic lancing devices are devices known for extracting blood samples for discerning the glucose levels of patients. The global diabetic lancing device market report by Market Research Future (MRFR) contains a comprehensive outlook backed by substantive drivers, opportunities, and restraints.
Market Outlook
The global Diabetic Lancing Device Market Profile is expected to touch a towering valuation by exhibiting 11% CAGR from 2017 to 2023 (forecast period). High cases of diabetes is expected to push the market demand for prevention and management of the disease. Rising awareness of self-monitoring devices combined with safety measures for prevention of acquiring infectious diseases among patients can bode well for the diabetic lancing device market growth.
Alarming numbers of diabetics and demand for effective glycemic management can induce the demand for diabetic lancing devices. Recommendations by doctors for regular testing of hemoglobin A1c (HbA1c) can result in a massive surge. One of the devices gaining prominence include Accu-chek by Roche Labs which sends out alerts to your phone for regular tests and easy insertion for lancet strips.
But emergence of non-invasive technology can pose a threat to the market growth.
Segmentation Analysis
The global diabetic lancing device market is segmented by type, gauge, penetration depth, and end-user.
By type, it is segmented into standard and safety lancets. By gauge, it is segmented into 17/18g, 21g, 23g, 25g, 28g, 30g, and others. By penetration depth, it is segmented into 0.8 mm to 1.0 mm, 1.1 mm to 1.5 mm, 1.6 mm to 2.0 mm, 2.1 mm to 2.5 mm, 2.5 mm to 3.0 mm, and others. By end-user, it is segmented into research & academic laboratories, hospitals & clinics, home care & home diagnostics, diagnostic centers & medical institutions, and others.
Regional Analysis
Europe, the Middle East & Africa (MEA), Asia Pacific (APAC), and the Americas are regions covered in the diabetic lancing device market report.
The Americas have captured a significant market share in 2016, with North America acting as one of the key contributors. High prevalence of diabetes will be the major market driver. According to the International Diabetes Federation (IDF), close to 29.2 million in the U.S. suffer from diabetes in 2015. Healthcare policies and expanded healthcare budget are future indicators of the region’s large scope for the global diabetic lancing device market.
Europe is predicted to hold a major hold for the global market due to changes in lifestyle and tandem development of drugs due to inflow of capital in research and development. Presence of prominent manufacturers of safety lancets and lancing devices can work in favor of the region.
On the other hand, the APAC region can exhibit a stellar CAGR during the assessment period due to increased healthcare spending by governments of India and China. According to the Novo Nordisk Education Foundation, the average HbA1c level of citizens in key major cities is higher than the usual level with diabetes management solutions being pivotal for reducing the number. Presence of large number of lancet manufacturers in China, South Korea, and India can influence the global diabetic lancing market valuation by a considerable degree.
Request For Free Sample Copy :
https://www.marketresearchfuture.com/sample_request/5507 
Competitive Outlook
MedExel Co., Ltd, VOGT MEDICAL, Abbott Laboratories, HTL-STREFA S.A, Terumo, Owen Mumford Ltd, Improve Medical, Bayer AG, Becton Dickinson, Perrigo Diabetes Care, Greiner Bio One, Novo Nordisk A S, Medtronic, Eli Lilly and Company, ARKRAY Inc., UltiMed, Inc., Allison Medical, Inc., Stat Medical, B. Braun Melsungen AG, Sarstedt AG & Co, Artsana S.p.a., F. Hoffmann-La Roche AG, Simple Diagnostics, Trividia Health, Sanofi, Terumo Corporation, and Ypsomed Holding AG are some of the noteworthy players in the global diabetic lancing device market
NOTE: Our Team of Researchers are Studying Covid19 and its Impact on Various Industry Verticals and Wherever Required We Will be Considering Covid19 Footprints for a Better Analysis of Markets and Industries. Cordially Get in Touch for More Details.
 
 
 
Posted by at No comments:

Obstructive Lung Disease Drugs Market Forecast : Drivers ,Restraints, Opportunities & Challenges 2023

Obstructive Lung Disease Market Research Report– By Disease Type (Asthma, Bronchitis, Copd), By Product Type (Inhalers, Nebulizers), By Drug Class (Combination Drug, Lta, Ics, Saba, Laba), By Route of Administration, By End User– Global Forecast till 2023
Market Highlights
The use of drugs has emerged as an effective solution for the treatment of COPD and asthma, which largely contributes to the growth of the global Obstructive Lung Disease Drugs Market Forecast. The market is driven by the growing COPD and asthmatic patient population, as well as the FDA approval for novel products and its wide acceptance. Increasing government initiatives to control COPD and asthma further, fuel the growth of this market.
Due to the rising instances of COPD across the globe, it has become indispensable for organizations to offer promising healthcare solutions to reduce health complications. With a considerable part of population being infected by the disease, renowned COPD drug manufacturers are facing the need to reduce inflammation and improve patient health outcomes.
Regional Analysis
Global obstructive lung disease consists of regions namely the Americas, Europe, Asia Pacific, and the Middle East and Africa.
North America together dominates the global asthma and COPD market followed by the European market. Rising prevalence of asthma and COPD due to pollution, changing lifestyle, and the entry of generic and novel therapies in the market.
Asia Pacific is anticipated to be the fastest growing market over the forecast period. Emerging economies such India, China due to industrialization, demographic changes, and urbanization are witnessing increased levels of pollution, thus favoring the rising prevalence of asthma and COPD population.
Segmentation
The obstructive lung disease is segmented on the basis of disease type, product type, drug class, route of administration and end-users.
On the basis of disease type, the market is segmented into asthma, bronchiectasis, bronchitis and chronic obstructive pulmonary disease (COPD), and others
On the basis of product type, market is segmented into inhalers, and nebulizers. Inhalers are divided into Drug Powder Inhalers (DPIs), Metered Dose Inhalers (MDIs), Soft Mist Inhalers (SMIs). Moreover, nebulizers are divided into compressor nebulizers, ultrasonic nebulizers, and mesh nebulizers
On the basis of drug class, the market is segmented into combination drugs, leukotriene antagonists (LTA), inhaled corticosteroids (ICS), anticholinergics, short acting beta agonists (SABA), long acting beta agonists (LABA), and others. Furthermore, the combination products is divided into seretide/advair, symbicort, relvar/breo ellipta, flutiform, dulera, and others. Leukotriene Antagonists (LTA) is divided into singulair and others. Inhaled Corticosteroids (ICS) is divided into qvar, pulmicort, aerospan, flovent, and others. Anticholinergics is divided into Spiriva and Others. Short Acting Beta Agonists (SABA) is divided into proair, ventolin, and others.
On the basis of route of administration, market is segmented into oral, inhaler, intravenous, subcutaneous, and others
On the basis of end-user, the market is segmented into hospitals & diagnostic centers, academic institutes, pharmaceutical & biotechnology companies and others.
Key Players
Some of key the players in the global obstructive lung disease market are GlaxoSmithKline (GSK) (U.K), Novartis AG (Switzerland), Merck & Co. (U.S), Abbott Laboratories (U.S), Boehringer Ingelheim (Germany), AstraZeneca (U.K), Roche Holding AG (Switzerland), Teva Pharmaceutical Industries (Israel), Vectura Group (U.K), Pfizer Inc. (U.S), Mylan (U.S.), Aerovance Inc. (U.S.), Alkermes Inc. (U.S.), Almirall SA. (U.S.), Genentech Inc. (U.S.), Sepracor, Inc. (U.S.), Skyepharma plc (U.S.).
NOTE: Our Team of Researchers are Studying Covid19 and its Impact on Various Industry Verticals and Wherever Required We Will be Considering Covid19 Footprints for a Better Analysis of Markets and Industries. Cordially Get in Touch for More Details.
Posted by at No comments:

Thumb Arthritis Market to Register Substantial Expansion by 2018 to 2023

Thumb Arthritis Market Research Report: By Type (Osteoarthritis, Rheumatoid) Diagnosis (Physical Examinations, Imaging, FNA) Treatment (Thumb Exercise, Medication, Surgery) End Users (Hospitals & Clinics, Retail Pharmacies) – Global Forecast Till 2023

Market Highlights

In thumb arthritis, the cushion-like cartilage inside the CMC joint breaks down, causing the bones to rub against each other. Increasing prevalence of thumb arthritis, growing geriatric and obese population, and rising healthcare expenditure are some of the major factors estimated to drive the market growth during the forecast period. A study was published in the HAND (American Association for Hand Surgery) journal in 2016, according to which the prevalence of the thumb CMC osteoarthritis was estimated to be around 8%-12% in the general population. However, the high cost of the surgical therapeutics along with related complications is estimated to restrain the market growth during the forecast period.
The Global Thumb Arthritis Market is expected to grow at an approximate CAGR of 8.1% during the forecast period.

Segmentation

The global thumb arthritis market is segmented on the basis of type, diagnosis, treatment, and end user. On the basis of the type, the market is segmented into osteoarthritis thumb arthritis, rheumatoid thumb arthritis, and others. On the basis of the diagnosis, the market is segmented into physical examinations, imaging, fine needle aspiration (FNA), and others. The imaging segment is sub-segmented into X-ray, computed tomography (CT), magnetic resonance imaging (MRI), and others.

On the basis of the treatment, the market is segmented into thumb exercise, medication, surgery, and others. The medication segment is sub-segmented into OCT medications, prescription medications, and others. The surgery segment is sub-segmented into trapeziectomy, osteotomy, and others.

On the basis of the end users, the market is segmented into hospitals & clinics, research organizations, retail pharmacies, and others.

Regional Analysis

The Americas dominate the global thumb arthritis market. A well-developed healthcare sector, growing geriatric population, and increasing healthcare expenditure are the major drivers for the growth of the global thumb arthritis market.

Europe holds the second largest thumb arthritis market owing to the availability of the funds for research, increasing surgery adoption rates, and growing patient population. According to the Office for National Statistics the geriatric population within the region is expected to grow and reach 20.5% of the total U.K population by 2026 from 18.0% in 2016.

Asia Pacific is the fastest growing region. Growing geriatric and obese population followed by the developing healthcare sector are boosting the market growth. Within the region, Australia holds a significant ratio of the obese population. However, the presence of the developing economies like India and China are marked by expanding healthcare sector. This is estimated to provide favorable backgrounds for the market growth
.
The Middle East and Africa region account for the least market share. This is mainly due to the presence of the poor African economies within the region, which have low per capita income and lack of the medical services. On the other, the Middle East holds the largest market share within the region.


Key Players

The key players in the global thumb arthritis market are inclusive of BioPro (U.S.), McKie Splints (U.S.), AbbVie Inc. (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Amgen Inc. (U.S.), Pfizer Inc. (U.S.), Carestream Health. (U.S.), General Electric Company (U.K), and others.

NOTE: Our Team of Researchers are Studying Covid19 and its Impact on Various Industry Verticals and Wherever Required We Will be Considering Covid19 Footprints for a Better Analysis of Markets and Industries. Cordially Get in Touch for More Details.
 
Posted by at No comments:

Turner Syndrome Market size by Industry Insight Analysis, Segments, Top Key Players, Drivers and Trends to 2023

Turner Syndrome Market research report, diagnosis (physical examination, prenatal testing, karyotyping), treatment (progesterone replacement therapy, psychological therapy), end users (hospitals & clinics, academic institutes) – global forecast till 2023
Market Highlights
Turner Syndrome Market is a rare disease in which one of the X chromosome is completely or partially missing. Some of the symptoms for the disease are webbed neck, lymphedema, and others. Increasing prevalence of the disease and rising female population are the major factors that drives the market during the forecast period.  Additionally, increasing FDA approvals and growing biotechnology sector followed by increasing awareness of the women health is expected to fuel the market growth. However, high annual treatment cost and related side effects is estimated to restrain the market growth during the forecast period. Additionally, low per capita healthcare expenditure by the middle and low income countries across the world is estimated to restrain the market growth.
Segmentation
The global turner syndrome market is segmented on the basis diagnosis, treatment, and end user.
On the basis of the diagnosis, the market is categorized into physical examination, prenatal testing, karyotyping and others. The prenatal testing segment, by diagnosis, is sub-segmented into ultrasound test, amniocentesis, chorionic villus sampling, and others.
On the basis of the treatment, the market is segmented into human growth hormone therapy, oestrogen replacement therapy, progesterone replacement therapy, psychological therapy, and others.
On the basis of the end user, the market is segmented into hospitals & clinics, academic institutes, research organization, and others.
Regional Analysis
America dominates the global turner syndrome market. Increasing adoption of new technologies and huge patient population along with rising healthcare expenditure and the presence of a developed economies drives the market growth within the region.
Europe stands second in the global turner syndrome market owing to rising research and development expenses and huge patient population. Moreover, growing biotech sector within the region fuels the market growth within the region.
Asia Pacific region is the fastest growing market due to increasing awareness for women health, rising healthcare expenditures and growing healthcare sector. Moreover, developing economies like India and China with growing healthcare sector are present within the region, helping the market to grow.
The Middle East & Africa has the least share in the global turner syndrome market. The presence of poor economies and stringent government policies, especially in the African region restrains the market growth within the region.
Key Players
Cooper Pharma (India), Pfizer Inc. (U.S.), Lilly USA, LLC (U.S.), Genentech, Inc. (U.S.), Novo Nordisk (Denmark), Smiths Medical (U.S.), Rocket Medical plc. (U.K), Medtronic (U.S.), Sanofi (France), and others are some of the key players in the global turner syndrome market.
NOTE: Our Team of Researchers are Studying Covid19 and its Impact on Various Industry Verticals and Wherever Required We Will be Considering Covid19 Footprints for a Better Analysis of Markets and Industries. Cordially Get in Touch for More Details.
Posted by at No comments:

Thursday, June 25, 2020

Americas Gastrointestinal Drugs Market Size, Share, Growing Growth Opportunities, Driving Factors With Top Players 2023

Gastrointestinal (GI) infections are common problems which are resolved rapidly but aggravate in certain healthcare settings. There are recorded cases of 3-6 million children dying due to gastroenteritis worldwide. Gastrointestinal agents are recommended by doctors and clinicians to alleviate problems caused in lupus, gastroesophageal reflux disease (GERD), and others. Market Research Future (MRFR) has focused on specific trends and GI diseases in the Americas gastrointestinal drugs market report while keeping a finger on drug developments by large pharmaceutical companies.

Market Outlook
The Americas Gastrointestinal Drugs Market is poised to reach a stellar size of USD 53.9 Bn by 2023. It can exhibit a CAGR of 5% from 2017 to 2023 (forecast period). The market is anticipated to gain high dividends from over-the-counter (OTC) drugs as well as high incidence of GI diseases. Large number of patients being diagnosed with GI in healthcare settings combined with change in diets due to deviating lifestyles pursued by patients can drive the market demand over the forecast period.

Studies conducted by private firms in collaboration with universities or research groups have placed ranitdine, omeprazole, and sodium alginate as highly recommended drugs for treating GI disorders with minimum adverse effects. Prescription of histamine blockers or proton inhibitors for treating symptoms of heartburn can augur favorably for the market.

Rising awareness levels of GI and its associated disorders, accessibility to these drugs, and a notable rise in research and development activities are other major drivers expected to facilitiate market growth. Need for novel medications for the treatment of the malady can provide an abundance of growth opportunities to players.

Segmentation Analysis
The Americas gastrointestinal drugs market is segmented by disease type, route of administration, drug category, and end-user.

By disease type, it is segmented into inflammatory bowel diseases, gastroesophageal reflux disease, and others. Inflammatory bowel diseases are further segmented into Crohn’s disease and ulcerative disease. Ulcertaive disease is sub-segmented into acute severe ulcerative colitis, left sided colitis, pancolitis, ulcerative proctitis, and proctosigmoiditis.

By route of administration, it is segmented into parenteral, rectal, and oral.
By drug category, it is segmented into anti-emetic, anti-inflammatory, acid neutralizers, laxatives & anti-diarrheal, and others. Acid neutralizers are segmented into proton pump inhibitors, H2 antagonists, antacid, and others.
By end-user, it is segmented into retail pharmacies, hospital pharmacies, and others.

Regional Analysis
North America and South America are regions taken into consideration in the compilation of the Americas gastrointestinal drugs market report.
The North America region is expected to remain dominant due to the large numbers of the elderly and increasing cases of GI diseases. Hectic lifestyles and changes in dietary patterns among patients in the region are major drivers of the market. Prevalence of chronic diseases which can cause GI diseases as a side-effect combined with supportive healthcare insurance policies which cover drug reimbursement can bolster the Americas gastrointestinal drugs market revenue till 2023. Rapid approvals by federal agencies as well as expansion of the product pipeline can work in favor of the Americas gastrointestinal drugs market.

Competitive Analysis
Major industry participants in the global whiskey market include Takeda Pharmaceutical Company Limited, Valeant Pharmaceuticals, Eisai Co., Ltd., Abbott Laboratories, AbbVie Inc., Allergan Plc, Janssen Biotech Inc., Bayer AG, Evoke Pharma, Sanofi, Boehringer Ingelheim GmbH, GlaxoSmithKline Plc., AstraZeneca, and others.
Partnerships, agreements, collaborations, and mergers & acquisitions are major strategies employed by these players to gain their edge in the market. Recently, AstraZeneca plc entered an agreement with Tillots Pharma for the development of Encort. Encort is a medicine for alleviating the pain levels of patients with Crohn’s disease. The agreement will allow Tillots to distribute the medicine by paying a considerable share to AstraZeneca for development and production of Encort capsules outside the U.S.


Industry News
Diroximel Fumarate, a novel iteration of fumarate, has showcased positive effects when tested in the clinical trial of patients with relapsing-remitting multiple sclerosis (RRMS). The study, a collaboration between Biogen Inc and Alkermes plc, has low adverse effects as compared to dimethyl fumarate.

NOTE: Our Team of Researchers are Studying Covid19 and its Impact on Various Industry Verticals and Wherever Required We Will be Considering Covid19 Footprints for a Better Analysis of Markets and Industries. Cordially Get in Touch for More Details.
Posted by at No comments:

Wednesday, June 24, 2020

CBD Oil Market Covering Competitive Scenario & Market Dynamics throughout 2024

CBD Oil (Cannabidiol Oil) Market: Information by Type (Hemp-Derived & Marijuana-Derived), Application (Cosmetics Industry, Food Industry, Pharmaceuticals Industry & Others) and Region (Americas, Europe, Asia-Pacific and Middle East &Africa) - Global Forecast till 2024

CBD Oil Market Analysis/CBD Oil Market Trends 

The global CBD Oil Market value is likely to touch USD 3782.32 million at a 38.45% CAGR between 2019- 2024, according to the recent Market Research Future (MRFR) report. CBD or cannabidiol is derived from cannabis. They are naturally found in marijuana plants. As opposed to cannabinoid or THC, CBD does not create any intoxication or high effect. Hemp-derived & marijuana-derived are the two types of CBD oil. Some of its applications include cosmetics, pharmaceuticals, food, and others. 

CBD Oil Market Drivers and Restraints 

Various factors are adding to the global CBD oil market growth. These factors, as per the new MRFR report, include rising cases of chronic diseases as well as associated complications, legalization of CBD in different regions, increasing funding for cannabinoid research, growing awareness about the benefits of CBD oil and its different applications, and demand for CBD infused cosmetics. 

On the contrary, strict government policies, coupled with the adverse effects of cannabis, are factors that may impede the CBD oil market growth during the forecast period. 


Market Segmentation 

The MRFR report provides an inclusive segmental analysis of the global CBD oil market based on application & type. 

Based on type, the CBD oil market has been segmented into hemp-derived & marijuana-derived. Among these, the CBD oil that is hemp-derived will spearhead the market over the forecast period. It is likely to touch USD 2,092.97 million by 2024. 

Based on the application, the CBD oil market has been segmented into cosmetics, pharmaceuticals, food, and others. Among these, the cosmetics segment will have the lions share in the market over the forecast period for the non-psychoactive as well as anti-inflammatory properties of CBD. Besides, CBD infused cosmetics have turned into a key trend these days, which is again adding market growth. 

Regional Analysis

Based on the region, the global CBD oil market covers the recent trends and growth opportunities across the Americas, Europe, the Asia Pacific (APAC), & the Middle East & Africa (MEA). Among these, the Americas will lead the market over the forecast period. Factors fuelling market growth include rising consumption of cannabis-based products, presence of top CBD oil product companies, rising legalization of the usage of marijuana products, and increasing awareness about the different health benefits of CBD oil. Besides, the availability of various CBD based products and efficient distribution channels, resulting in easy accessibility are also adding market growth. The US is the chief contributor in the region. 

The global CBD oil market in Europe is predicted to have the second-largest share over the forecast period for the increasing awareness about the different clinical applications of cannabis. 

The global CBD oil market in the APAC region is likely to grow at a quick rate over the forecast period. Factors fuelling the market growth in the region include various hemp manufacturing plants being set up in China, the biggest cultivator of hemp, legalization of cannabis, and industry players, especially in the cosmetics & personal care industry targeting emerging economies for improving their profitability and sales. 

The global CBD oil market in the Middle East & Africa is predicted to have the smallest share during the forecast period for certain side effects of taking cannabis, illegal use of marijuana, and strict government policies. 


Key Players 

Eminent players profiled in the global CBD oil market report include Folium Biosciences (US), Canopy Growth Corporation (US), Curaleaf Holdings, Inc. (US), Aphria Inc. (Canada), Medical Marijuana, Inc. (US), ENDOCA (Netherlands), MedMen Enterprises Inc. (US), Kazmira LLC (US), Freedom Leaf, Inc. (US), CBD American Shaman (US), Charlotte's Web Holdings, Inc. (US), Aurora Cannabis (US), Green Roads of Florida, LLC (US), CV Sciences, Inc. (US), and others. 

NOTE: Our Team of Researchers are Studying COVID-19 and its Impact on Various Industry Verticals and Wherever Required We Will be Considering COVID-19 Footprints for a Better Analysis of Markets and Industries. Cordially Get in Touch for More Details.
Posted by at No comments:

Gene Therapy Market : Market Segments, Dynamics, Size, Supply & Demand, Current Trends and Forecast 2019-2025

Gene Therapy Market Landscape 

The Gene Therapy Market size in 2018 was valued at USD 524 million. It is likely to grow at a whopping 40.7% CAGR between 2019- 2025, as per the Market Research Future's (MRFR) new report. Gene therapy comprises replacing, repressing, and repairing dysfunctional genes that cause disease. The aim of this promising treatment is in re-establishing the normal function. This therapy helps to treat different genetic diseases such as inherited disorders, namely cancer & viral infections, and some specific genetic diseases, namely muscular dystrophy & cystic fibrosis. 

Market Drivers and Restraints 

Numerous factors are propelling the global gene therapy market growth. These factors, as per the new MRFR report, comprise increasing funds for gene therapy research, availability of favorable reimbursements, increasing cases of cancer & other target diseases, and strategic collaborations & product launches made by key players for staying ahead in the competition. Besides, rising cases of target diseases, large investments made by top market players, and robust product pipeline are also adding market growth. 

On the contrary, strict regulatory policies coupled with high product development cost are factors that may deter the gene therapy market growth over the forecast period as per the gene therapy market forecast. 


Market Segmentation

The global gene therapy market has been segmented based on indication, product, and end user. 

By product, the gene therapy market is segmented into yescarta, zynteglo, luxturna, imlygic, kymriah, zolgensma, strimvelis, and others. 

By indication, the gene therapy market is segmented into oncology, genetic disorders/diseases, and others. Among these, the oncology segment will have a major share in the market over the forecast period. The robust cancer gene therapy pipeline, coupled with surging cancer cases, is adding to the growth of the segment. 

By end user, the gene therapy market is segmented into hospitals and clinics, the specialty treatment center, & others. Among these, hospitals & clinics will lead the market over the forecast period. The burgeoning number of hospitals, coupled with hospitals & clinics being the foremost choice to treat diseases, is boosting the growth of this segment. 


Regional Analysis

Based on the region, the global gene therapy market report covers the recent trends and growth opportunities across Europe, North America, the Asia Pacific (APAC), and the Middle East and Africa (MEA). Of these, North America will have lions share in the market over the forecast period for the rising cases of chronic diseases, increasing healthcare expenditure, advanced & innovative healthcare infrastructure, presence of eminent market players, and availability of favorable reimbursements. 

The global gene therapy market in Europe is predicted to have favorable growth over the forecast period for industry players coming up with innovative product launches, top companies in the region extending product distribution by securing approval from various regulatory bodies, and increasing expenditure for gene and cell therapy companies in the UK. 

The global gene therapy in the Asia Pacific region is likely to grow at a fast pace during the forecast period. The rising government initiatives for the healthcare sector development, presence of top market players in the region, launch & approval of various gene therapy products, rising prevalence of chronic diseases, and growing awareness about gene therapy are adding market growth. 

The global gene therapy market in the Middle East and Africa is predicted to hold the smallest share over the forecast period for restricted healthcare infrastructure in the region. 

Key Players

Eminent players in the global gene therapy market include Orchard Therapeutics plc (UK), Novartis AG (Switzerland), Lonza (Switzerland), CEVEC (Germany), Amgen, Inc. (US), Gilead Sciences, Inc. (US), Thermo Fisher Scientific Inc. (US), Spark Therapeutics, Inc. (US), Bristol-Myers Squibb Company (US), Celgene Corporation (US),and uniQure N.V. (Netherlands). 
NOTE: Our Team of Researchers are Studying COVID-19 and its Impact on Various Industry Verticals and Wherever Required We Will be Considering COVID-19 Footprints for a Better Analysis of Markets and Industries. Cordially Get in Touch for More Details.
Posted by at No comments:

Migraine Treatment Market Growth, Size, Share, Historical Growth, Analysis, Development Status, Opportunities and Forecast To 2022

Migraine Market information, by types (Episodic and Chronic), by treatment type (Preventive and Abortive), by drug class (Triptans, Ergots, and Others) – Global Forecast to 2022
Market Analysis
The global Migraine Treatment Market Growth is anticipated to grow at an impressive CAGR between 2013-2022, states the latest Market Research Future (MRFR) report. Migraine is basically a neurological condition which can result in multiple symptoms. It is characterized by a debilitating, intense headache. Often migraine runs in families and can affect every age group. Sensitivity to sound and light, difficulty speaking, tingling or numbness, vomiting, and nausea are common symptoms of migraines.
Migraine may begin during childhood, or it may not occur until early adulthood. Generally, women are more likely to suffer from migraines than men. Migraine with aura or classic migraines and without aura or common migraine are the two common categories of migraine. The pain mostly affects the area of the forehead, is usually on one side of the head, yet may shift, or occur on both sides of the head.
Numerous factors are pushing the growth of the market such as growing awareness regarding the prevention and also treatment of migraine, rising healthcare expenditure, launch and FDA approval of new migraine drugs, rising cigarette consumption, increasing intake of hormonal medications, lifestyle changes, rising disease prevalence, and stressed lifestyle. Additional factors propelling the growth of the migraine market include accelerating economic growth, rising prevalence of migraine, increasing female population, demand for hormonal medications, high unmet needs, and launch of calcitonin gene-related peptide (CGRP).
On the contrary, different side effects from migraine drugs, stringent government regulations, regulatory challenges, scarcity of proper diagnosis, rising preference of alternative therapies, and increasing investment in drug R&D are factors that may restrict the migraine market growth during the forecast period.
Market Segmentation
The global migraine market has been segmented in terms of drug class, types, and treatment types.
By types, the migraine market is segmented into chronic as well as episodic. Of these, the episodic segment will lead the market during the forecast period owing to its increasing prevalence.
By treatment types, the migraine market is segmented into abortive and preventive. Of these, the abortive segment will dominate the market during the forecast period for the ease of self-administration in those with migraines accompanied by vomiting and nausea.
By drug class, the migraine market is segmented into ergots, triptans, and others. Of these, triptans will have maximum share in the market during the forecast period.
Request For Free Sample Copy :
https://www.marketresearchfuture.com/sample_request/2381
Regional Analysis
The global migraine market report is geographically distributed across the following key regions: North America, Europe, the Asia Pacific (APAC), and the Rest of the World (RoW). Among these, North America will have the lion’s share in the market during the forecast period. Various factors propelling the growth of the migraine market in the region include the launch of CGRP based therapies, adoption of novel therapeutics, huge target population, especially in the US, increasing R&D activities in the region, and increasing incidence of migraine. The US is the major contributor in the region.
The migraine market in the APAC region will have favorable growth during the forecast period. Various factors propelling the growth of the migraine market in the region include increasing healthcare expenditure, growing disease awareness, huge underserved population, and low-cost production of drugs.
The migraine market in Europe will have a notable growth during the forecast period for rising stress levels, changing lifestyles, and rising incidence of hormonal imbalance.
The migraine market in the RoW will have stable growth during the forecast period.
Browse Complete Toc :
 https://www.marketresearchfuture.com/reports/migraine-market-2381 
Key Players
Notable players profiled in the global migraine market report include Pfizer, Inc., Eisai Inc., Impax Laboratories, Eli Lilly and Company, Abbott Laboratories, Allegan, Luitpold Pharmaceuticals, Klaria, Johnson and Johnson, Kowa Pharmaceuticals America, GlaxoSmithKline plc., OptiNose, Meda, AstraZeneca plc, Merck, and others. Key players have used specific strategies to stay head and shoulders above others in the competition, such as collaborations, expansions, mergers and acquisitions, research and development activities, new product launches, and more.
Industry News
October 2019: Eli Lilly’s Reyvow has received FDA approval to treat acute migraines. It is the only and foremost medicine that has received approval from the FDA to treat acute migraines.
NOTE: Our Team of Researchers are Studying Covid19 and its Impact on Various Industry Verticals and Wherever Required We Will be Considering Covid19 Footprints for a Better Analysis of Markets and Industries. Cordially Get in Touch for More Details.
Posted by at No comments:

Ulcerative Colitis Market Trends to Expand with Significant CAGR During 2022

Ulcerative Colitis Market Information, by type (Ulcerative Proctitis, Proctosigmoiditis, Left-Sided Colitis, Pancolitis or Universal Colitis, and Fulminant Colitis), by Medication (5-Aminosalicylates, Steroids, Purine Analogs, Immunomodulators, and Biologics) – Forecast to 2022
Market Research Future published a Half-Cooked research report on “Global Ulcerative Colitis Market Trends Research Report – Forecast till 2022” – Market Analysis, Scope, Stake, Progress, Trends and Forecast to 2022.
Global  Ulcerative Colitis Market  – Overview
The market for ulcerative colitis is growing due to increasing demand for biologics for treating bowel disorders such as ulcerative collates and is propelling the overall market growth of global ulcerative market. Higher inclination for symptomatic therapeutic and drugs over surgeries, increase in patient assistance programs, better treatment and management of inflammatory bowel diseases, the arrival of advanced drugs in the market owing to healthier investments in R&D programs are some of the key trends governing the market. Moreover, drug manufacturers are actively focusing on advanced products having higher efficiency. The growing patient population is an additional factor anticipated to influence the market growth between 2016 and 2022. Also the increase in patient assistance programs is a major driver of the market. The provision of these programs by vendors will upsurge the preference for branded drugs because the out-of-pocket burdens would be less as the drugs are obtained at lower costs.
Global Ulcerative Colitis Market – Regional Analysis
The market of ulcerative colitis is much higher in the Americas region. In Americas, North America commands the largest market share of global ulcerative colitis market and is expected to grow at the same pace. Asia Pacific shows sufficient cases recoded for the disease due to lack of infrastructure and awareness and is expected to be the fastest growing segment with the highest CAGR due to continuous improvement in healthcare sector and increasing awareness among people. According to the US Center for Disease Control, there is an ulcerative colitis prevalence of 238 per 100,000 adults. The number of ulcerative colitis patients is increasing in emerging economies as per the development in technology, these developing or emerging economies are expected to account for the larger market share in coming future.
Allergan, Inc., AbbVie Inc., Takeda Pharmaceutical Company Limited, Bayer AG, UCB S.A., Perrigo Company plc, Pfizer Inc., Johnson & Johnson Services, Inc., Ferring B.V., Janssen Biotech, and Merck are some of the leading players at the cutting edge of the competition in the market of ulcerative Colitis, globally.

Key developments
Companies are continuously developing new products to capture the market globally. Thus major players invest more in research and development activity, in order to lead the global market. In this regards, market players undertake various strategic approaches.
Johnson & Johnson Services Inc.
September, 2016: Acclarent Inc., a subsidiary of Johnson & Johnson, received FDA approval for ACCLARENT AERA Eustachian Tube Balloon Dilation System. It is a first FDA-approved device to treat Eustachian Tube Dysfunction effectively.
March, 2016: Ethicon, a medical device company of the Johnson & Johnson, acquired NeuWave Medical, Inc.
June, 2015: Verb Surgical Company was created by the collaboration of Ethicon and Verily.
March, 2015: Ethicon, a medical device company of the Johnson & Johnson, enter into a collaboration with Google, Inc.
NOTE: Our Team of Researchers are Studying Covid19 and its Impact on Various Industry Verticals and Wherever Required We Will be Considering Covid19 Footprints for a Better Analysis of Markets and Industries. Cordially Get in Touch for More Details.
Posted by at No comments:
Subscribe to: Posts (Atom)